P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This study aimed to compare the efficacy and safety of P2Y12 inhibitor monotherapy versus
extended dual antiplatelet therapy (DAPT) following 12-month of DAPT in patients undergoing
percutaneous coronary intervention (PCI) with bioresorbable scaffold (BRS)